COMMUNIQUÉS West-GlobeNewswire

A study of elite athletes shows that ColdZyme provides protection as evidenced by fewer sick days and lost training days, as well as improved quality of life

21/06/2017 - 08:35

News Enzymatica Study Elite Athletes Eng 170621 This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they [...]

Mithra Pharmaceuticals: MITHRA LAUNCHES A CAPITAL INCREASE BY MEANS OF A PRIVATE PLACEMENT VIA AN ACCELERATED BOOKBUILD OFFERING

21/06/2017 - 08:05

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL PRESS RELEASE REGULATED INFORMATION - INSIDE [...]

Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance

21/06/2017 - 07:15

AMG 334 (erenumab) is the first anti-CGRP monoclonal antibody developed for migraine prevention to receive EMA regulatory filing acceptance Filing is supported by a comprehensive clinical program of over 2,600 migraine [...]

MITHRA COMPLETES RECRUITMENT FOR ADDITIONAL ESTELLE® SAFETY STUDY

21/06/2017 - 07:15

PRESS RELEASE MITHRA COMPLETES RECRUITMENT FOR ADDITIONAL estelle® SAFETY studY Safety study is part of the development of Estelle®, Mithra's combined oral contraceptive candidate Aim of the study is to analyze a broad [...]

Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes

20/06/2017 - 23:57

Bagsværd, Denmark, 20 June 2017 - Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) has completed its meeting regarding the [...]

Galapagos increases share capital through warrant exercises

20/06/2017 - 22:00

Mechelen, Belgium; 20 June 2017, 22.00 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from warrant exercises. Galapagos issued 52,030 new ordinary [...]

Oriola Corporation starts repurchase of its own class B shares in connection with the company's incentive schemes

20/06/2017 - 17:00

Oriola Corporation Stock Exchange Release 20 June 2017 18.00 Oriola Corporation starts repurchase of its own class B shares in connection with the company's incentive schemes The Board of Directors of Oriola Corporation [...]

New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs

20/06/2017 - 15:30

Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity DUBLIN and VIENNA - June 20, 2017 - Medtronic plc ( [...]

The Jackson Laboratory and Crown Bioscience Announce Global Pre-Clinical Research Agreement

20/06/2017 - 15:00

BAR HARBOR, Maine and SANTA CLARA, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience (CrownBio), a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554), and The Jackson Laboratory (JAX [...]

Holaira Announces Company Name Change to Nuvaira

20/06/2017 - 15:00

Company Adds Shane Gleason to Executive Team MINNEAPOLIS, June 20, 2017 (GLOBE NEWSWIRE) -- Holaira , a developer of medical devices to treat obstructive lung diseases, today announced that it has changed its name to [...]

The Jackson Laboratory et Crown Bioscience annoncent un accord mondial de recherche préclinique

20/06/2017 - 15:00

BAR HARBOUR (Maine) et SANTA CLARA (Californie), le 20 juin 2017 (GLOBE NEWSWIRE) - Crown Bioscience (CrownBio), filiale en propriété exclusive de Crown Bioscience International (TWSE : symbole boursier 6554) et The [...]

Holaira annonce le changement de dénomination de la société pour devenir Nuvaira

20/06/2017 - 15:00

Shane Gleason joint l'équipe de direction de la société MINNEAPOLIS, le 20 juin 2017 (GLOBE NEWSWIRE) - Holaira , développeur de dispositifs médicaux destinés à traiter les maladies pulmonaires obstructives, a annoncé [...]

Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC

20/06/2017 - 15:00

Helsinn Group Announces Upcoming Presentation of Phase III data in NEPA (netupitant/palonestron) at MASCC/ISOO Congress in Washington DC Data demonstrates the non-inferiority of NEPA versus an aprepitant (APR)/ [...]

Nokia launches portfolio of digital health products designed to inspire people to take control of their health

20/06/2017 - 09:10

Nokia expands in digital health; company announces largest line of connected consumer health products New products include Nokia Body BMI Wi-Fi connected scale, Nokia BPM+ soft-cuff blood pressure monitor, new Nokia [...]

Galapagos' R&D Update 2017: rapidly advancing our product candidates

20/06/2017 - 07:30

Filgotinib Darwin 3: improved activity, consistent safety parameters for filgotinib Ph2 studies initiated in 6 new indications Cystic fibrosis Three different triple combos in development Successful completion of Ph1 [...]

Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval

20/06/2017 - 07:15

RTH258 achieved the primary efficacy endpoint of non-inferiority to aflibercept in mean change in BCVA from baseline to week 48[1],[2] in two head-to-head pivotal Phase III studies[3],[4] 57% and 52% of patients [...]

Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden

20/06/2017 - 07:10

Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by study of over 3,700 [...]

argenx receives second preclinical milestone payment in collaboration with LEO Pharma

20/06/2017 - 07:00

June 20, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

NEOVACS ANNONCE LA FIN DU RECRUTEMENT DES PATIENTS POUR SON ETUDE CLINIQUE DE PHASE IIB DANS LE TRAITEMENT DU LUPUS

20/06/2017 - 07:00

NEOVACS ANNONCE LA FIN DU RECRUTEMENT DES PATIENTS POUR SON ETUDE CLINIQUE DE PHASE IIB DANS LE TRAITEMENT DU LUPUS Perspective de publication des résultats cliniques au cours du deuxième trimestre 2018 Paris et Boston [...]